EXAGEN INC. (XGN) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US30068X1037
EXAGEN INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 66.58 m USD |
| Gross profit | 38.80 m USD |
| Operating income | -14.07 m USD |
| EBIT | -15.87 m USD |
| Net income | -19.95 m USD |
| Diluted EPS – continuing operations | -0.93 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About EXAGEN INC.
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
More stocks
- Black Mammoth Metals Corp (BMM.V)
- Draganfly Inc (DPRO)
- IBI Lion SOCIMI S.A. (YIBI.MC)
- WLM Participações e Comércio de Máquinas e Veículos S.A (WLMM3.SA)
- BANK OF THE JAMES FINANCIAL GROUP INC (BOTJ)
- Amadeus Fire (AAD.DE)
- Taiwan Fructose Co Ltd (4207.TWO)
- Pinnacle Bank (PBNK)
- CareCloud, Inc. (CCLD)
- Mcrae Inds Cl A (MCRAA)
- Molecular Partners AG (MOLN.SW)
- PIE Co., LTD. (452450.KQ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.